

UNDERSTANDING THE AESTHETIC IMPACT OF MEDICATION-DRIVEN WEIGHT LOSS

The use of prescription weight loss medications is set to increase globally, with \$100 billion GLP-1 sales forecasted globally by 2030 and will have a considerable impact on the aesthetic market¹.

23%


of patients using weight loss medications are already using or considering aesthetic treatments²

62%


of patients using weight loss medications get aesthetic treatments following a healthcare professional recommendation²

As the pure-play dermatology category leader, Galderma commissioned new research, surveying patients to deepen the understanding of this new category.

Men and women



Ages



Located in



THE IMPACT OF MEDICATION-DRIVEN WEIGHT LOSS ON THE FACE

Nearly half (48%) of patients reported significant facial changes due to medication-driven weight loss treatments, with changes typically observed 3-6 months following treatment, and as early as 1-2 months².



Sagging or loose skin²



Tired looking appearance²



More lines²



Dull skin, loss of radiance/glow²



Hollow appearance²



Loss of jawline definition²



"I wanted to get rid of my double chin, but I didn't expect I'd get a turkey neck."

"I noticed that my face felt kind of longer. The skin was a little bit looser around my jawline. It felt droopier."

"I wanted to look healthier, so if people keep telling me I look tired, what have I achieved?"

"I didn't feel like myself anymore. I didn't like to be photographed. I didn't feel good about myself. My self-esteem was low."

Facial changes vary across demographics

Older patients

55-65

reported more sagging and loose skin compared to those under 55²

Menopausal women experience:^{2*}

Higher levels of sagging skin

20% vs. 14%

A slimmer face

39% vs. 30%

Less radiant skin

15% vs. 11%

*versus entire patient sample

HOW THE PHENOMENON IS IMPACTING GLP-1 PATIENTS' AESTHETICS PERCEPTIONS AND PLANS

ALREADY EXISTING AESTHETIC USERS:

60%

have undergone treatments to address changes on their face²

49%

plan to undergo aesthetic procedures when they reach their weight loss goal²

AESTHETIC CONSIDERERS:

1/3

would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey²

AN INTEGRATED, HOLISTIC APPROACH IS NEEDED

More than

60%

of patients show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals counsel to support them in their weight loss journey²

They seek treatment to

TIGHTEN
BRIGHTEN
LIFT
ADD VOLUME

and have a high likelihood to use Galderma's portfolio of aesthetic solutions to address their concerns.

48%

of patients would try Sculptra^{®2}

41%

of patients would try Restylane^{®2}



Final nine-month data from a first-of-its-kind clinical trial,* conducted by Galderma, confirms that a treatment regimen of Restylane[®] Lyft[™] or Restylane[®] Contour^{™**} and Sculptra[®] delivers improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss.³

Galderma continues to lead the response to addressing the facial aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs.

The trial used the SHAPE Up Holistic Individualized Treatment (HIT[™]) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Restylane and Sculptra portfolios to optimize aesthetic outcomes while prioritizing patient satisfaction.

- **The Restylane Lyft or Restylane Contour and Sculptra regimen demonstrated skin quality improvements, with Restylane Lyft significantly improving skin hydration and Sculptra significantly improving skin radiance through Month 9.³**
- Subject satisfaction[†] – which was reported by the majority of patients[‡] as early as Week 4 – was maintained through Month 9:³
 - **85.7%** of patients[‡] agreed their face looked **less gaunt/sunken³**
 - **88.6%** of patients[‡] agreed they "loved" how the treatment **maintained their facial structure³**
 - **88.6%** of patients[‡] agreed they "loved" **the regenerative effects** of Sculptra treatment³
 - **88.6%** of patients[‡] agreed they **looked better now than before** the injection regimen³
 - **91.4%** of patients[‡] **would recommend the injection regimen** to others after weight loss and to those with loose, sagging facial skin³

* Phase IV, multicenter, open-label, prospective study that assessed the efficacy, safety, and patient satisfaction of the SHAPE Up Holistic Individualized Treatment (HIT[™]) regimen over a 9-month period in patients (N=35) experiencing facial volume loss following treatment with prescription weight-loss medications.

** Restylane Contour is known as Restylane Volyme[™] in countries outside of the U.S.

† Subjects who responded with "agree" or "strongly agree" on questionnaire. Subjects were treated with either Restylane Lyft or Restylane Contour and Sculptra.

‡ Patients= clinical trial participants.

With deep skin knowledge, aesthetic expertise and individualized patient-centric treatment approach, Galderma is uniquely positioned to support this evolution, through new data and knowledge, in close collaboration with leading healthcare professionals.

1 JP Morgan report. The increase in appetite for obesity drugs. November 2023.

2 Galderma MAC Research. 2024.

3 Data on file. GLI.04.US.SL.036 clinical study report. Dallas, TX: Galderma Laboratories, L.P. 2025.